Screening and diagnosis of HBV in low-income and middle-income countries

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 11, 2016, Pages 643-653

  Allain, Jean Pierre ^a   Opare Sem, Ohene ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS ANTIBODY;

ACTIVE INFECTION MONITORING; ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; CLINICAL OUTCOME; CONVALESCENCE; DISEASE MARKER; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INACTIVE CHRONIC HEPATITIS B; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MIXED INFECTION; MONITORING; NONHUMAN; OCCULT HEPATITIS B VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SAMPLING; SCREENING; VIRUS REACTIVATION; ANTIBODY PRODUCTION; ANTIVIRAL RESISTANCE; COINFECTION; COMPLICATION; DEVELOPING COUNTRY; EARLY DIAGNOSIS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MASS SCREENING; METABOLISM; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; VIROLOGY; VIRUS ACTIVATION;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIVIRAL AGENTS; BIOMARKERS; COINFECTION; DEVELOPING COUNTRIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EARLY DIAGNOSIS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MASS SCREENING; VIRUS ACTIVATION;

EID: 84987660682     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2016.138     Document Type: Review

References (157)

1. Bekondi C, et al. HBV immunization, and vaccine coverage among hospitalized children in Cameroon, Central African Republic, and Senegal: a cross-sectional study. BMC Infect. Dis. 15, 267 (2015
2. Bosch F. X, Ribes J, Cléries R, & Díaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 9, 191-211 (2005
3. Parkin D. M, et al. (eds) Cancer in Africa: epidemiology, and prevention. IARC Scientific Publication No. 153 (IARC, 2016
4. Lu J, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv. Res. 13, 37 (2013
5. Dan Y. Y, Aung M. O, & Lim S. G. The economics of treating chronic hepatitis B in Asia. Hepatol. Int. 2, 284-295 (2008
6. Jazwa A, et al. Cost-benefit Comparison of Two Proposed Overseas Programs for Reducing Chronic Hepatitis B Infection among Refugees: Is Screening Essential? Vaccine 33, 1393-1399 (2015
7. Kania D, et al. Combining rapid diagnostic tests, and dried blood spot assays for point of care testing of human immunodeficiency virus, hepatitis B, and hepatitis C infections in Burkina Faso, West Africa. Clin. Microbiol. Infect. 19, E533-E541 (2013
8. Komada K, et al. Seroprevalence of chronic hepatitis B, as determined from dried blood spots, among children, and their mothers in central Lao People's Democratic Republic: a multistage, stratified cluster sampling survey. Int. J. Infect. Dis. 36, 21-26 (2015
9. Vinikoor M. J, et al. Hepatitis B viral load in dried blood spots: a validation study in Zambia. J. Clin. Virol. 72, 20-24 (2015
10. Njai H. F, et al. Validation of rapid point of care (POC) tests for detection of hepatitis B surface antigen in field, and laboratory settings in the Gambia, Western Africa. J. Clin. Microbiol. 53, 1156-1163 (2015
11. Smith A, Sabidó M, Camey E, Batres A, & Casabona J. Lessons learned from integrating simultaneous triple point of care screening for syphilis, hepatitis B, and HIV in prenatal services through rural outreach teams in Guatemala. Int. J. Gynaecol. Obstet. 130 (Suppl. 1), S70-S72 (2015
12. Biswas R, et al. Comparative sensitivity of HBV NATs, and HBsAg assays for detection of acute HBV infection. Transfusion 43, 788-798 (2003
13. Minegishi K, et al. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang. 84, 287-291 (2003
14. Raimondo G, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49, 652-657 (2008
15. Alper C. A. The human immune response to hepatitis B surface antigen. Exp. Clin. Immunogenet. 12, 171-181 (1995
16. Seremba E, et al. Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda. J. Med. Virol. 82, 1334-1340 (2010
17. Allain J. P, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 101, 2419-2425 (2003
18. Owusu-Ofori S, et al. Predonation screening of blood donors with rapid tests: implementation, and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 45, 133-140 (2005
19. Chevaliez S, et al. Performance of a new rapid test for the detection of hepatitis B surface antigen in various patient populations. J. Clin. Virol. 59, 89-93 (2014
20. Scheiblauer H, et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes, and HBsAg subtypes. Vox Sang. 98, 403-414 (2010
21. Shivkumar S, Peeling R, Jafari Y, Joseph L, & Pai N. P. Rapid point of care first-line screening tests for hepatitis B infection: a meta-Analysis of diagnostic accuracy (1980-2010). Am. J. Gastroenterol. 107, 1306-1313 (2012
22. Randrianirina F, et al. Evaluation of the performance of four rapid tests for detection of hepatitis B surface antigen in Antananarivo, Madagascar. J. Virol. Methods 151, 294-297 (2008
23. Mutocheluh M, et al. Risk factors associated with hepatitis B exposure, and the reliability of five rapid kits commonly used for screening blood donors in Ghana. BMC Res. Notes 7, 873 (2014
24. Khuroo M. S, Khuroo N. S, & Khuroo M. S. Accuracy of rapid point of care diagnostic tests for hepatitis B surface antigen - A systematic review, and meta-Analysis. J. Clin. Exp. Hepatol. 4, 226-240 (2014
25. Mendy M, et al. Hepatitis B surface antigenaemia, and alpha-foetoprotein detection from dried blood spots: applications to field-based studies, and to clinical care in hepatitis B virus endemic areas. J. Viral Hepat. 12, 642-647 (2005
26. Candotti D, Opare-Sem O, Rezvan H, Sarkodie F, & Allain J. P. Molecular, and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with, and without elevated alanine aminotransferase. J. Viral Hepat. 13, 715-724 (2006
27. Candotti D, Danso K, & Allain J. P. Maternofetal transmission of hepatitis B virus genotype E in Ghana, West Africa. J. Gen. Virol. 88, 2686-2695 (2007
28. Sarkodie F, et al. Screening for viral markers in volunteer, and replacement blood donors in West Africa. Vox Sang. 80, 142-147 (2001
29. Huang P, et al. Seroepidemiology of hepatitis B virus infection, and impact of vaccination. World J. Gastroenterol. 21, 7842-7850 (2015
30. Zhang Y, et al. Hepatitis B surface antigen prevalence among 12, 393 rural women of childbearing age in Hainan Province, China: a cross-sectional study. Virol. J. 10, 25 (2013
31. Zhong L, et al. The estimation of prevalence, and risk factors of hepatitis B virus infection among blood donors in Chengdu, China. J. Med. Virol. 88, 260-267 (2016
32. Li W, et al. The estimation of prevalence, incidence, and residual risk of transfusion-Transmitted human hepatitis B infection from blood donated at the Anhui blood center, China, from 2009 to 2011. PLoS ONE 8, e73472 (2013
33. Hourfar M. K, et al. Sensitivity, and specificity of Anti-HBc screening assays - which assay is best for blood donor screening? Int. J. Lab. Hematol. 31, 649-656 (2009
34. El Ghitany E. M, & Farghaly A. G. Evaluation of commercialized rapid diagnostic testing for some Hepatitis B biomarkers in an area of intermediate endemicity. J. Virol. Methods 194, 190-193 (2013
35. Villar L. M, et al. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. J. Med. Virol. 83, 1522-1529 (2011
36. Shimelis T, et al. Hepatitis B virus infection among people attending the voluntary counselling, and testing centre, and anti-retroviral therapy clinic of St Paul's General Specialised Hospital, Addis Ababa, Ethiopia. Sex. Transm. Infect. 84, 37-41 (2008
37. Zheng X, et al. High prevalence of anti-hepatitis B core antigen in hepatitis B virus-vaccinated Chinese blood donors suggests insufficient protection but little threat to the blood supply. Transfusion 55, 890-897 (2015
38. Behzad-Behbahani A, et al. Anti-HBc, and HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J. Med. Res. 123, 37-42 (2006
39. Muselmani W, Habbal W, & Monem F. Prevalence of anti-HBc alone among Syrian blood donors. J. Infect. Dev. Ctries 8, 1013-1015 (2014
40. Akinbami A. A, et al. Seroprevalence of hepatitis B e antigen (HBe antigen), and B core antibodies (IgG anti HBcore, and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria. BMC Res. Notes 5, 167 (2012
41. Antar W, El Shokry M. H, Abd El Hamid W. A, & Helmy M. F. Significance of detecting anti-HBc among Egyptian male blood donors negative for HBsAg. Transfus. Med. 20, 409-413 (2010
42. Asim M, et al. Significance of anti-HBc screening of blood donors, and its association with occult hepatitis B virus infection: implications for blood transfusion. Indian J. Med. Res. 132, 312-317 (2010
43. Bhatti F. A, Ullah Z, Salamat N, Ayub M, & Ghani E. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion 47, 74-79 (2007
44. Sarin S. K, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1-98 (2015
45. Vlachogiannakos J, & Papatheodoridis G. V. HBV: Do I treat my immunotolerant patients? Liver Int. 36 (Suppl. 1), 93-99 (2016
46. Ducancelle A, et al. High endemicity, and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon. PLoS ONE 8, e80346 (2013
47. Pu Z, et al. Epidemiological characteristics of the carriers with coexistence of HBsAg, and anti-HBs based on a community cohort study. J. Viral Hepat. 23, 286-293 (2016
48. Seo S. I, et al. Coexistence of hepatitis B surface antigen, and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study. J. Med. Virol. 86, 124-130 (2014
49. Phikulsod S, et al. One-year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion 49, 1126-1135 (2009
50. Louisirirotchanakul S, et al. Occult hepatitis B virus infection in Thai blood donors. Transfusion 51, 1532-1540 (2011
51. Candotti D, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation, and potential mechanisms of occurrence. Gut 61, 1744-1753 (2012
52. Stramer S. L, et al. Nucleic acid testing to detect HBV infection in blood donors. N. Engl. J. Med. 364, 236-247 (2011
53. Liu J, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect. Dis. 16, 80-86 (2016
54. He F, et al. The serum anti-HBs level among children who received routine hepatitis B vaccination during infancy in Mianyang City, China: a cross-sectional study. Viral Immunol. 29, 40-48 (2016
55. Wang F, et al. The long-Term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China. Vaccine 33, 2704-2709 (2015
56. Aghakhani A, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World J. Pediatr. 7, 358-360 (2011
57. Salama I. I, et al. Persistence of protection to hepatitis B vaccine, and response to booster dose among children, and adolescents in Dakahleya-Egypt. Egypt. J. Immunol. 21, 13-26 (2014
58. Sallam T. A, et al. Hepatitis B virus carrier rate, prevalence, and susceptibility, and impact of immunization program among households in the city of Taiz, Yemen. Vaccine 30, 5564-5568 (2012
59. Rey-Cuille M. A, et al. Hepatitis B virus exposure during childhood in Cameroon, Central African Republic, and Senegal after the integration of HBV vaccine in the expanded program on immunization. Pediatr. Infect. Dis. J. 32, 1110-1115 (2013
60. Saffar H, et al. Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth: impact on the epidemiology of hepatitis B infection in Iran. Hepat. Mon. 14, e17263 (2014
61. Zheng X, et al. Seroprevalence of transfusion-Transmissible infectious agents among volunteer blood donors between 2006, and 2012 in Zhejiang, China. Blood Transfus. 13, 401-410 (2015
62. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009
63. Lok A. S, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review, and meta-Analysis. Hepatology 63, 284-306 (2016
64. Garbuglia A. R, et al. Comparison of Versant HBV DNA 3.0, and COBAS AmpliPrep-COBAS TaqMan assays for hepatitis B DNA quantitation: possible clinical implications. J. Virol. Methods 146, 274-280 (2007
65. Mohamed S, et al. Dried blood spot sampling for hepatitis B virus serology, and molecular testing. PLoS ONE 8, e61077 (2013
66. Zhang S, et al. A one-step dipstick assay for the on site detection of nucleic acid. Clin. Biochem. 46, 1852-1856 (2013
67. Bao H, et al. Rapid high-Throughput genotyping of HBV DNA using a modified hybridization-extension technique. Phys. Chem. Chem. Phys. 15, 18179-18184 (2013
68. Mao X, et al. Colorimetric detection of hepatitis B virus (HBV) DNA based on DNA-Templated copper nanoclusters. Anal. Chim. Acta 909, 101-108 (2016
69. Ola S. O, et al. Occult HBV infection among a cohort of Nigerian adults. J. Infect. Dev. Ctries 3, 442-446 (2009
70. Kitab B, et al. Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver Int. 34, e144-e150 (2014
71. Lukhwareni A, Burnett R. J, Selabe S. G, Mzileni M. O, & Mphahlele M. J. Increased detection of HBV DNA in HBsAg-positive, and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J. Med. Virol. 81, 406-412 (2009
72. N'Dri-Yoman T, et al. Occult HBV infection in untreated HIV-infected adults in Côte d?Ivoire. Antivir. Ther. 15, 1029-1034 (2010
73. Peebles K, et al. Pediatric HIV-HBV coinfection in Lusaka, Zambia: prevalence, and short-Term treatment outcomes. J. Trop. Pediatr. 61, 464-467 (2015
74. Barth R. E, et al. Presence of occult HBV, but near absence of active HBV, and HCV infections in people infected with HIV in rural South Africa. J. Med. Virol. 83, 929-934 (2011
75. Allain J. P, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 49, 1868-1876 (2009
76. Allain J. P, & Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Transfus. 7, 174-182 (2009
77. Vermeulen M, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated, and observed window period risk. Transfusion 52, 880-892 (2012
78. Li C, et al. Prevalence, and prevalence trends of transfusion transmissible infections among blood donors at four Chinese regional blood centers between 2000, and 2010. J. Transl. Med. 10, 176 (2012
79. Niazi S. K, Bhatti F. A, Salamat N, Ghani E, & Tayyab M. Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan. Transfusion 55, 1803-1811 (2015
80. Ren F. R, et al. Hepatitis B virus nucleic acid testing in Chinese blood donors with normal, and elevated alanine aminotransferase. Transfusion 51, 2588-2595 (2011
81. Oluyinka O. O, et al. Occult hepatitis B virus infection in Nigerian blood donors, and hepatitis B virus transmission risks. PLoS ONE 10, e0131912 (2015
82. Moresco M. N, et al. Occult hepatitis B virus infection among blood donors from the Brazilian Amazon: implications for transfusion policy. Vox Sang. 107, 19-25 (2014
83. Zheng X, et al. Characterization of occult hepatitis B virus infection from blood donors in China. J. Clin. Microbiol. 49, 1730-1737 (2011
84. Gou H, et al. Evaluation of an individual-donation nucleic acid amplification testing algorithm for detecting hepatitis B virus infection in Chinese blood donors. Transfusion 55, 2272-2281 (2015
85. Vermeulen M, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 49, 1115-1125 (2009
86. Chatterjee K, et al. Individual donor nucleic acid testing for blood safety against HIV 1, and hepatitis B, and C viruses in a tertiary care hospital. Natl Med. J. India 25, 207-209 (2012
87. Tsoi W. C, Lelie N, & Lin C. K. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay. Transfusion 53, 2477-2488 (2013
88. Vermeulen M, et al. Sensitivity of individual-donation, and minipool nucleic acid amplification test options in detecting window period, and occult hepatitis B virus infections. Transfusion 53, 2459-2466 (2013
89. Seed C. R, et al. Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme. Vox Sang. 108, 113-122 (2015
90. Satake M, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 47, 1197-1205 (2007
91. Yuen M. F, et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin. Infect. Dis. 52, 624-632 (2011
92. Allain J. P, et Al. Infectivity of Blood Products from Donors with Occult Hepatitis B Infection (OBI). Transfusion 53, 1405-1415 (2013
93. Malmström S, Berglin-Enquist I, & Lindh M. Novel method for genotyping hepatitis B virus on the basis of TaqMan real-Time PCR. J. Clin. Microbiol. 48, 1105-1111 (2010
94. Song L. W, et al. Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping. Anal. Chem. 87, 5173-5180 (2015
95. Mercier M, Laperche S, Girault A, Sureau C, & Servant-Delmas A. Overestimation of incidence of hepatitis B virus mixed-genotype infections by use of the new line probe INNO-LiPA genotyping assay. J. Clin. Microbiol. 49, 1154-1156 (2011
96. Yang R, et al. INNO-LiPA HBV genotyping is highly consistent with direct sequencing, and sensitive in detecting B/C mixed genotype infection in Chinese chronic hepatitis B patients, and asymptomatic HBV carriers. Clin. Chim. Acta 411, 1951-1956 (2010
97. Li H. M, et al. Hepatitis B virus genotypes, and genome characteristics in China. World J. Gastroenterol. 21, 6684-6697 (2015
98. Saikia A, et al. Molecular epidemiology of HBV infection in chronic hepatitis B virus infected patients in northeast India. J. Med. Virol. 87, 1539-1548 (2015
99. Yousif M, et al. Genotyping, and virological characteristics of hepatitis B virus in HIV-infected individuals in Sudan. Int. J. Infect. Dis. 29, 125-132 (2014
100. Chamni N, et al. Genetic characterization, and genotyping of hepatitis B virus (HBV) isolates from donors with an occult HBV infection. Vox Sang. 107, 324-332 (2014
101. Awan Z, et al. Pattern, and molecular epidemiology of Hepatitis B virus genotypes circulating in Pakistan. Infect. Genet. Evol. 10, 1242-1246 (2010
102. Ochwoto M, et al. Genotyping, and molecular characterization of hepatitis B virus in liver disease patients in Kenya. Infect. Genet. Evol. 20, 103-110 (2013
103. Mello F. C, et al. Hepatitis B virus genotypes circulating in Brazil: molecular characterization of genotype F isolates. BMC Microbiol. 7, 103 (2007
104. Abdelnabi Z, Saleh N, Baraghithi S, Glebe D, & Azzeh M. Subgenotypes, and mutations in the s, and polymerase genes of hepatitis B virus carriers in the West Bank, Palestine. PLoS ONE 9, e113821 (2014
105. Mahgoub S, Candotti D, El Ekiaby M, & Allain J. P. Hepatitis B virus (HBV) infection, and recombination between HBV genotypes D, and E in asymptomatic blood donors from Khartoum, Sudan. J. Clin. Microbiol. 49, 298-306 (2011
106. Garmiri P, Loua A, Haba N, Candotti D, & Allain J. P. Deletions, and recombinations in the core region of hepatitis B virus genotype E strains from asymptomatic blood donors in Guinea, West Africa. J. Gen. Virol. 90, 2442-2451 (2009
107. Tanwar S, & Dusheiko G. Is there any value to hepatitis B virus genotype analysis? Curr. Gastroenterol. Rep. 14, 37-46 (2012
108. Lin C. L, & Kao J. H. The clinical implications of hepatitis B virus genotype: recent advances. J. Gastroenterol. Hepatol. 26 (Suppl. 1), 123-130 (2011
109. Chu C. J, Hussain M, & Lok A. S. Hepatitis B Virus Genotype B Is Associated with Earlier HBeAg Seroconversion Compared with Hepatitis B Virus Genotype C. Gastroenterology 122, 1756-1762 (2002
110. Wen J, et al. Hepatitis B virus genotype, mutations, human leukocyte antigen polymorphisms, and their interactions in hepatocellular carcinoma: a multi centre case-control study. Sci. Rep. 5, 16489 (2015
111. Shimakawa Y, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut http://dx.doi.org/10.1136/gutjnl-2015-309892 (2015
112. Kew M. C, Kramvis A, Yu M. C, Arakawa K, & Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub Saharan Africans. J. Med. Virol. 75, 513-521 (2005
113. Kao J. H. Diagnosis of hepatitis B virus infection through serological, and virological markers. Expert Rev. Gastroenterol. Hepatol. 2, 553-562 (2008
114. Asabe S, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83, 9652-9662 (2009
115. Baumert T. F, Thimme R, & von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 13, 82-90 (2007
116. Komiya Y, et al. Minimum infectious dose of hepatitis B virus in chimpanzees, and difference in the dynamics of viremia between genotype A, and genotype C. Transfusion 48, 286-294 (2008
117. Chu C. M, & Liaw Y. F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-Term follow up. Hepatology 45, 1187-1192 (2007
118. Simonetti J, et al. Clearance of hepatitis B surface antigen, and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51, 1531-1537 (2010
119. Liaw Y. F, & Chu C. M. Hepatitis B virus infection. Lancet 373, 582-592 (2009
120. Han S. H, & Tran T. T. Management of chronic hepatitis B: an overview of practice guidelines for primary care providers. J. Am. Board Fam. Med. 28, 822-837 (2015
121. Martinot-Peignoux M, et al. Serum hepatitis B virus DNA levels, and liver histology in inactive HBsAg carriers. J. Hepatol. 36, 543-546 (2002
122. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57, 167-185 (2012
123. Hadziyannis S. J, & Vassilopoulos D. Hepatitis B e Antigen-negative Chronic Hepatitis B. Hepatology 34, 617-624 (2001
124. World Health Organization. Guidelines for the prevention, care, and treatment of persons with chronic hepatitis B infection (WHO, 2015
125. Gibney K. B, Torresi J, Lemoh C, & Biggs B. A. Isolated core antibody hepatitis B in sub-Saharan African immigrants. J. Med. Virol. 80, 1565-1569 (2008
126. Raimondo G, Caccamo G, Filomia R, & Pollicino T. Occult HBV infection. Semin. Immunopathol. 35, 39-52 (2013
127. Allain J. P. Occult hepatitis B virus infection. Transfus. Clin. Biol. 11, 18-25 (2004
128. Squadrito G, Cacciola I, Alibrandi A, Pollicino T, & Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J. Hepatol. 59, 696-700 (2013
129. Pollicino T, & Raimondo G. Occult hepatitis B infection. J. Hepatol. 61, 688-689 (2014
130. Liaw Y. F. Natural history of chronic hepatitis B virus infection, and long-Term outcome under treatment. Liver Int. 29 (Suppl. 1), S100-S107 (2009
131. Raimondi S, Maisonneuve P, Bruno S, & Mondelli M. U. Is response to antiviral treatment influenced by hepatitis B virus genotype? J. Hepatol. 52, 441-449 (2010
132. Venook A. P, Papandreou C, Furuse J, & de Guevara L. L. The incidence, and epidemiology of hepatocellular carcinoma: a global, and regional perspective. Oncologist 15 (Suppl. 4), 5-13 (2010
133. Chen J. D, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma, and liver related death. Gastroenterology 138, 1747-1754 (2010
134. Chu C. M, & Liaw Y. F. Incidence, and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am. J. Gastroenterol. 104, 1693-1699 (2009
135. Abbas Z, & Siddiqui A. R. Management of hepatitis B in developing countries. World J. Hepatol. 3, 292-299 (2011
136. Jafri S. M, & Lok A. S. Antiviral therapy for chronic hepatitis B. Clin. Liver Dis. 14, 425-438 (2010
137. Leung N. W, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33, 1527-1532 (2001
138. Perillo R, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32, 129-134 (2000
139. Corsa A. C, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin. Gastroenterol. Hepatol. 12, 2106-2112.e1 (2014
140. Lemoine M, Nayagam S, & Thursz M. Viral hepatitis in resource-limited countries, and access to antiviral therapies: current, and future challenges. Future Virol. 8, 371-380 (2013
141. Reijnders J. G, Perquin M. J, Zhang N, Hansen B. E, & Janssen H. L. Nucleos(t)ide Analogues only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients with Chronic Hepatitis B. Gastroenterology 139, 491-498 (2010
142. Agarwal K, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J. Hepatol. 62, 533-540 (2015
143. Castera L. Transient elastography, and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J. Viral Hepat. 16, 300-314 (2009
144. Kruger F. C, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S. Afr. Med. J. 101, 477-480 (2011
145. Lesmana C. R, et al. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting. J. Clin. Pathol. 64, 916-920 (2011
146. Bonnard P, et al. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am. J. Trop. Med. Hyg. 82, 454-458 (2010
147. Tarigan E, et al. S Index, and APRI score to predict liver fibrosis chronic in hepatitis B, and C patients. Indonesian J. Gastroenterol. Hepatol. Dig. Endos. 14, 64-68 (2013
148. Chan H. L, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J. Viral Hepat. 16, 36-44 (2009
149. Lemoine M, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis, and cirrhosis in patients with chronic HBV infection in West Africa. Gut 65, 1369-1376 (2016
150. Li Q, et al. The gamma-glutamyl-Transpeptidase to platelet ratio does not show advantages than APRI, and Fib 4 in diagnosing significant fibrosis, and cirrhosis in patients with chronic hepatitis B: a retrospective cohort study in China. Medicine (Baltimore) 95, e3372 (2016
151. Zeng X, et al. Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B. Croat. Med. J. 56, 272-279 (2015
152. Buti M, et al. Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis. J. Hepatol. 48 (Suppl. 2), S33 (2008
153. Piroth L, et al. Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis B in HIV-infected Patients (EPIB 2005 Study). AIDS 21, 1323-1331 (2007
154. Chang J. J, et al. Impaired quality of the hepatitis B virus (HBV)-specific T cell response in human immunodeficiency virus type 1 HBV coinfection. J. Virol. 83, 7649-7658 (2009
155. Sherman M. Strategies for managing coinfection with hepatitis B virus, and HIV. Cleve. Clin. J. Med. 76 (Suppl. 3), S30-S33 (2009
156. Ranjbar R, Davari A, Izadi M, Jonaidi N, & Alavian S. M. HIV/HBV co infections: epidemiology, natural history, and treatment: a review article. Iran. Red Crescent Med. J. 13, 855-862 (2011
157. Wiersma S, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 31, 755-761 (2011